Pollens - grasses, bluegrass, kentucky (june) poa pratensis - Biologic Drug Details

Summary for pollens - grasses, bluegrass, kentucky (june) poa pratensis

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, bluegrass, kentucky (june) poa pratensis

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract Non-Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, bluegrass, kentucky (june) poa pratensis Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, bluegrass, kentucky (june) poa pratensis Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, bluegrass, kentucky (june) poa pratensis Derived from Patent Text Search

No patents found based on company disclosures

Pollens - grasses, bluegrass, kentucky (june) poa pratensis Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Therapeutic Drugs: A Focus on the Broader Biologics Market

Introduction

The biologic therapeutic drugs market is undergoing significant transformation, driven by advances in technology, changing regulatory landscapes, and evolving consumer needs. While the specific focus on biologics derived from pollens of grasses like Kentucky bluegrass (Poa pratensis) is not a dominant segment, understanding the broader market dynamics can provide insights into potential opportunities and challenges.

Global Market Overview

The global market for biologic therapeutic drugs is expected to experience robust growth. From $452.9 billion in 2023, the market is projected to reach $823.4 billion by 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period[1].

Key Market Segments

Biologic therapeutic drugs encompass several key segments, including:

Monoclonal Antibodies (mAb)

Monoclonal antibodies are a significant segment within the biologics market. They are widely used in treating autoimmune diseases, cancer, and other conditions. The segment's growth is driven by strong launches and the lack of off-patent competition in incumbent therapy areas[3].

Therapeutic Proteins

Therapeutic proteins, including insulin and growth hormones, are another crucial segment. These proteins are essential in treating diabetes, growth disorders, and other metabolic conditions.

Vaccines

Vaccines are a vital component of the biologics market, especially with the recent advancements in mRNA technology and the global response to pandemics.

Therapeutic Areas

The biologics market is dominated by three major therapeutic areas:

Autoimmune Diseases

Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, account for a significant portion of biologic revenue. New launches and the absence of biosimilar competition in these areas have driven growth[3].

Diabetes

Biologics for diabetes, including insulin analogs and combination treatments, are another major segment. However, the introduction of biosimilars is expected to impact growth in this area.

Oncology

Oncology is a rapidly growing segment, with immuno-oncology treatments and antibody-drug conjugates being key drivers. The oncology pipeline is rich with promising candidates, and this segment is expected to continue its strong growth trajectory[3].

Impact of Biosimilars

Biosimilars are set to significantly impact the biologics market. Once major biologic products face biosimilar competition, prices are expected to drop, leading to increased access but also dampening overall market growth. However, this competition will also enable spending in other therapeutic areas[3].

Technological Advancements

Technological advancements are a key driver of the biologics market. Single-use technologies, cell and gene therapy tools, and reagents are areas seeing significant growth. For instance, the global market for single-use technologies for biopharmaceuticals is expected to grow at a CAGR of 11.6% from 2024 to 2029[1].

Regulatory Environment

The regulatory environment plays a crucial role in the biologics market. Changes in regulations and the approval process can significantly impact the market. For example, the introduction of biosimilars is regulated differently across various regions, affecting market dynamics[3].

Sustainability and ESG Trends

Sustainability and Environmental, Social, and Governance (ESG) practices are becoming increasingly important in the biopharmaceutical industry. Companies are focusing on consumer attitudes, ESG scores, and sustainable practices to ensure long-term viability and market trust[1].

Clinical Trials and R&D Activity

Ongoing clinical trials and R&D activities are critical for the development of new biologics. The pipeline is rich with promising candidates, especially in oncology and other non-traditional biologic disease areas. This R&D activity is a key factor in the market's growth and diversification[1].

Financial Trajectory

The financial trajectory of the biologics market is positive, driven by strong launches, a robust pipeline, and increasing demand. Here are some key financial highlights:

• The global biologics market was valued at $452.9 billion in 2023 and is expected to reach $823.4 billion by 2028[1].
• The market has seen a 70% growth in the last five years, reaching $232 billion in 2016[3].
• The top 10 biologic therapies account for 36% of all biologic spending, with the three largest therapy areas (autoimmune, diabetes, oncology) worth over $110 billion[3].

Market Opportunities and Challenges

Opportunities

• Expanding Therapeutic Focus: Biologics are broadening their therapeutic focus, entering new disease areas such as hypercholesterolemia and severe asthma[3].
• Technological Advancements: Advances in single-use technologies, cell and gene therapy, and other areas are driving innovation and efficiency[1].
• Growing Demand: Increasing demand for biologics, especially in emerging markets, is driving growth.

Challenges

• Biosimilar Competition: The introduction of biosimilars will lead to increased competition and downward pricing pressure[3].
• Regulatory Changes: Changes in regulatory environments can impact the approval and launch of new biologics.
• High Development Costs: The development of biologics is costly and time-consuming, posing a significant challenge for companies.

Conclusion

The biologic therapeutic drugs market is poised for significant growth, driven by technological advancements, expanding therapeutic areas, and increasing demand. While the specific segment related to pollens from grasses like Kentucky bluegrass is not a major focus, the broader market dynamics offer valuable insights into the opportunities and challenges that could impact any biologic product.

Key Takeaways

• The global biologics market is expected to grow from $452.9 billion in 2023 to $823.4 billion by 2028.
• Monoclonal antibodies, therapeutic proteins, and vaccines are key segments driving market growth.
• Autoimmune diseases, diabetes, and oncology are the dominant therapeutic areas.
• Biosimilars will significantly impact market dynamics by increasing competition and reducing prices.
• Technological advancements and R&D activities are crucial for market growth.

FAQs

Q: What is the projected growth rate of the global biologics market from 2023 to 2028? A: The global biologics market is expected to grow at a compound annual growth rate (CAGR) of 12.7% from 2023 to 2028[1].

Q: Which therapeutic areas dominate the biologics market? A: The three largest therapeutic areas are autoimmune diseases, diabetes, and oncology, accounting for over half of all biologic revenue[3].

Q: How will the introduction of biosimilars impact the biologics market? A: The introduction of biosimilars will lead to increased competition, downward pricing pressure, and potentially wider access to biologics for patients[3].

Q: What role do technological advancements play in the biologics market? A: Technological advancements, such as single-use technologies and cell and gene therapy tools, are driving innovation and efficiency in the biologics market[1].

Q: What are the key challenges facing the biologics market? A: Key challenges include biosimilar competition, regulatory changes, and the high costs associated with developing biologics[3].

Sources

1. BCC Research: Biologic Therapeutic Drugs: Technologies and Global Markets.
2. PLOS ONE: Transcriptome analysis of Kentucky bluegrass subject to drought and ethephon treatment.
3. IQVIA: Disruption and maturity: The next phase of biologics.